International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

By Franck Pagès, Bernhard Mlecnik, F. Marliot, Gabriela Bindea, F. Ou, C. Bifulco, A. Lugli, I. Zlobec, T. Rau, M. D. Berger and 89 more. The Lancet, 2018

1,778 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, methodology): “Immunoscore had the highest relative contribution to the risk of all clinical parameters, including the UICC TNM classification system.(70) Therefore, Immunoscore could help refine the prognosis of early colon cancer patients in conjunction with the TNM scoring [III, C].”
Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front (2019, result): “contrast to prior studies in CRC and other cancers, including lung, breast, ovarian and melanoma, in which relative abundances of these two cell types were correlated with outcome (Fridman et al., 2012; Galon et al., 2014; Galon et al., 2012; Pages et al., 2018).”
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology (2022, background): “Histopathology image data harbor prognostically important information such as lymphocyte count 45,46 , chromatin patterns 47”